2025 annual financial data
Inhibikase Therapeutics 2025 Financial results
Direct answer
Revenue was 0 USD.
Operating income was -51,974,283 USD and net income was -48,259,189 USD.
Operating cash flow was -27,786,464 USD.
Get free Inhibikase Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 0 USD
- Operating income
- -51,974,283 USD
- Net income
- -48,259,189 USD
- Operating cash flow
- -27,786,464 USD
Explore related company data
View all 2025 financial metricsView RevenueView Operating incomeView Net incomeView Operating cash flowView Revenue growthView Operating income growthView Net income growthView Operating cash flow growthView Operating marginView Net marginView Operating cash flow marginView all Inhibikase Therapeutics financial years